STOCK TITAN

Eton director sells 50,000 shares near $60

Eton Pharmaceuticals, Inc. (ETON) director Paul V. Maier reported multiple transactions on 2026-08-28.

(Neutral)
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (ETON) director Paul V. Maier reported multiple transactions on 2026-08-28. He exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share and 12,500 shares at $7.31 per share, receiving common stock.

On the same date, he sold an aggregate of 50,000 common shares in open-market transactions: 36,387 shares at a weighted average price of $58.64 (range $58.50–$58.97), 13,485 shares at $60.21 (range $60.00–$61.00), and 128 shares at $61.77 (range $61.10–$61.98).

Positive

  • None.

Negative

  • None.
Insider MAIER PAUL V
Role Director
Sold 50,000 shs ($2.95M)
Approx. gross sale proceeds $2.95M
Approx. exercise cost $280K
Type Security Shares Price Value
Exercise Employee Stock Option F3 50,000 $0.00 $0.00
Exercise Employee Stock Option F6 12,500 $0.00 $0.00
Exercise Common Stock 50,000 $3.78 $189K
Sale Common Stock F1, F2 36,387 $58.64 $2.13M
Sale Common Stock F1, F4 13,485 $60.21 $812K
Sale Common Stock F1, F5 128 $61.77 $8K
Exercise Common Stock 12,500 $7.31 $91K
Holdings After Transaction: Employee Stock Option — 0 contracts (Direct); Common Stock — 72,245 shares (Direct)
Footnotes (6)
  1. F1. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
  2. F2. The shares were sold in multiple trades at prices ranging from $58.50 to $58.97. The price reported above reflects the weighted average sales price.
  3. F3. The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-07-2022) until fully vested.
  4. F4. The shares were sold in multiple trades at prices ranging from $60.00 to $61.00. The price reported above reflects the weighted average sales price.
  5. F5. The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price.
  6. F6. The shares subject to the option vested in four equal quarterly installments from the date of grant (02-20-2019) until fully vested.
Options exercised - shares at $3.78 50,000 shares at $3.78 per share Employee Stock Option exercise into common stock on 2026-08-28
Options exercised - shares at $7.31 12,500 shares at $7.31 per share Employee Stock Option exercise into common stock on 2026-08-28
Common shares sold at $58.64 36,387 shares at $58.64 per share Open-market sale on 2026-08-28; trades ranged $58.50–$58.97
Common shares sold at $60.21 13,485 shares at $60.21 per share Open-market sale on 2026-08-28; trades ranged $60.00–$61.00
Common shares sold at $61.77 128 shares at $61.77 per share Open-market sale on 2026-08-28; trades ranged $61.10–$61.98
Total common shares sold 50,000 shares Aggregate of three open-market sale tranches on 2026-08-28
Option grant vesting (2022 grant) 48 equal monthly installments from 2-07-2022 Vesting schedule for 50,000-share Employee Stock Option
Option grant vesting (2019 grant) Four equal quarterly installments from 02-20-2019 Vesting schedule for 12,500-share Employee Stock Option
Employee Stock Option financial
"security_title: "Employee Stock Option""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
weighted average sales price financial
"The price reported above reflects the weighted average sales price."

FAQ

What insider transactions did ETON director Paul V. Maier report on August 28, 2026?

He exercised options for 62,500 shares of ETON common stock (50,000 at $3.78, 12,500 at $7.31) and sold 50,000 shares in open-market trades at weighted average prices between $58.64 and $61.77, with price ranges detailed in the filing footnotes.

How many ETON options did Paul V. Maier exercise and at what strike prices?

He exercised employee stock options covering 50,000 shares at an exercise price of $3.78 per share and 12,500 shares at $7.31 per share, receiving ETON common stock upon exercise.

How many ETON shares did Paul V. Maier sell on August 28, 2026 and at what prices?

He sold a total of 50,000 ETON common shares: 36,387 at a weighted average price of $58.64, 13,485 at $60.21, and 128 at $61.77. Footnotes state these were executed in multiple trades within specified price ranges.

Were Paul V. Maier’s ETON transactions under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox is marked false, and the footnotes do not reference a trading plan, so the reported August 28, 2026 transactions are not indicated as being made pursuant to a Rule 10b5-1 trading plan.

What vesting terms applied to the ETON options exercised by Paul V. Maier?

Footnotes state the 50,000-share option granted 2-07-2022 vested in 48 equal monthly installments, and the 12,500-share option granted 02-20-2019 vested in four equal quarterly installments until fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MAIER PAUL V

(Last)(First)(Middle)
C/O ETON PHARMACEUTICALS, INC.
21925 W. FIELD PARKWAY, SUITE 235

(Street)
DEERPARK ILLINOIS 60010-7208

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
08/28/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/28/2026M50,000A$3.78109,745D
Common Stock08/28/2026S36,387D$58.64(1)(2)73,358D
Common Stock08/28/2026S13,485D$60.21(1)(4)59,873D
Common Stock08/28/2026S128D$61.77(1)(5)59,745D
Common Stock08/28/2026M12,500A$7.3172,245D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option$3.7808/28/2026M50,00002/07/2022(3)02/06/2032Common Stock50,000$00D
Employee Stock Option$7.3108/28/2026M12,50002/20/2019(6)02/19/2029Common Stock12,500$00D
Explanation of Responses:
1. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
2. The shares were sold in multiple trades at prices ranging from $58.50 to $58.97. The price reported above reflects the weighted average sales price.
3. The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-07-2022) until fully vested.
4. The shares were sold in multiple trades at prices ranging from $60.00 to $61.00. The price reported above reflects the weighted average sales price.
5. The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price.
6. The shares subject to the option vested in four equal quarterly installments from the date of grant (02-20-2019) until fully vested.
Remarks:
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.
/s/ Judith Matthews08/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)